| CTD Holdings (OTCQB: CTDH) Announces New Data Presented at Annual Gathering of Patients and Families Tackling Niemann-Pick Disease Type C |
| |
|
CTD Holdings (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, posted its presentation from the annual Family Support and Medical Conference organized by the National Niemann-Pick Disease Foundation (NNPDF).
Key Quote: “Our data suggest that Trappsol®Cyclo™ is safe when administered intravenously at the doses we are using in our clinical trials, and our data show encouraging effects in addressing NPC symptoms, including ataxia, behavioral manifestations of the disease, and liver dysfunction. Our newest data, which have not been presented until now, suggest that the drug clears cholesterol from liver cells of NPC patients based on histological results: this is the first time that we have been able to visualize clearance of cholesterol in liver cells of NPC patients following intravenous administration of our drug.” – Dr. Sharon Hrynkow, Chief Scientific Officer and Senior Vice President for Medical Affairs
The Backstory: Niemann-Pick type C Disease (NPC) is a rare genetic disease affecting 1 in 100,000 live births globally. NPC affects every cell in the body due to the defect in the NPC protein which is responsible for cholesterol processing in the cell. Because of the NPC defect in this disease, cholesterol accumulates abnormally in every cell in the body, causing symptoms in the brain, liver, spleen, lung and other organs. NPC is ultimately a fatal disease. CTD supports three clinical trial programs using its proprietary cyclodextrin drug, Trappsol® Cyclo™, administered intravenously, in the United States, the United Kingdom, Sweden, Israel and Italy for the treatment of NPC. Both main trials are nearing completion of enrollment, and one extension study is active with a second extension study soon to be active.
Disclosure
CTD Holdings (CTDH) is a client of RedChip Companies, Inc. CTDH agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| cbdMD (NYSE American: YCBD) Reports Q3 Net Sales Increase 42% Sequentially to Over $8 Million |
| |
|
cbdMD (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, reported net sales for the quarter ended June 30 increased 42% sequentially to more than $8 million. The company also provided guidance for the fiscal years ending September 30, 2019 and 2020 of $24M-$26M and $80M-$90M, respectively.
Why It Matters: In addition to posting extremely impressive performance for the June quarter, cbdMD’s guidance puts the company on track to reach the five-year earn-out hurdle of $300 million in aggregate net revenue by the end of calendar 2021, a full two years ahead of schedule.
Key Quote: “To secure our leadership position in the CBD industry and create a truly world-class brand in one of the most exciting market opportunities globally, we continue to strategically invest in growing valuable partnerships and sponsorships with world-class athletes that resonate with our customers.” – Scott Coffman, co-CEO
The Backstory: cbdMD products are now on the shelves of more than 3,000 retailers in the US. With a growing roster of impressive celebrity athlete sponsorships, cbdMD has proven its ability to navigate the challenging marketing landscape of CBD. With a reach to target audiences of this magnitude, the company appears well on its way to becoming the leading CBD brand.
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| Catasys (NASDAQ: CATS) Reports Q2 Revenue Up 135% Year-Over-Year |
| |
|
Catasys (NASDAQ: CATS), a leading AI and technology-enabled healthcare company, reported second quarter revenue up 135% year-over-year and up 13% from Q1 2019.
Why It Matters: Underlying Catasys’ strong growth is its growing outreach pool of eligible members, which as of August 2019 stands at 112,000, up 49% from the 75,000 reported at the end of the first quarter this year.
Key Quote: “Our outreach pool surpassed the milestone 100,000 eligible lives during the 2019 second quarter as we once again achieved strong year-over-year growth in enrollment and revenues as a result of expansion within existing agreements with health plan partners.” – Terren Peizer, Chairman & CEO
What’s Next: Catasys nearly matched its entire 2018 revenue level in the just the first half of 2019. The company’s growing outreach pool is expected to serve as the primary driver for new enrollment growth in the second half of 2019 and into next year. Despite already reporting impressive growth, the company views 2019 as a transitional year and expects exponential growth in 2020 and beyond.
Disclosure
Catasys (NASDAQ: CATS) is a client of RedChip Companies, Inc. CATS agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Reports Q2 Revenue of $2.5M |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures and markets advanced digital technology products for law enforcement, homeland security and commercial security applications, reported revenue of $2.5 million for the second quarter, down from the year ago period as competition remains high in its law enforcement segment.
Key Quote: “We continue to face increased challenges for our in-car and body-worn systems due to our competitors releasing new products with advanced features, maintaining their product price cuts and, in some cases, infringing on our patents.” – Stan Ross, CEO
What’s Next: Digital Ally continues to focus efforts on its commercial business opportunities, where it is finding increasing traction. The company won the 2019 Golden Eagle Award at the National Sports Safety and Security Conference & Exhibition for its body cam system at Met Life Stadium in Rutherford, NJ. More recently, the company secured a multi-year agreement with the Kansas City Chiefs Football Club to provide the Chiefs’ security personnel with similar turnkey technology.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| SinglePoint (OTCQB: SING) Reports Triple-Digit Revenue Growth in Q2 |
| |
|
SinglePoint (OTCQB: SING), a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration, reported second quarter revenue more than doubled from the same period last year.
Key Quote: “We are very excited about the growth and path we are on. This is another step in the right direction for SinglePoint. We look forward to showing an even larger increase in Q3 as we will have the addition of Direct Solar projects that have closed and been funded. Everyone in the company has done a wonderful job and it's showing in the growth of revenue and number of opportunities being presented.” – Will Ralston, President
What’s Next: The big growth driver for SinglePoint has been its recent acquisition of Direct Solar, which was completed in May 2019. Using a Rocket Mortgage style business model, investors could expect to see not only the top line continue to improve, but ultimately the bottom line as well.
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services.
|
|
| |
|
| Immuron (NASDAQ: IMRN) to Commence Non-Deal Roadshow |
| |
|
Immuron Ltd. (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, is set to begin a comprehensive roadshow to investment institutions, analysts and shareholders.
Why It Matters: The non-deal roadshow should increase awareness of the Immuron opportunity amongst US investors.
The Backstory: Immuron is focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. Immuron has a novel and safe technology platform with one commercial asset generating revenue. In Australia, Travelan® is a listed medicine on the Australian Register of Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travellers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection in accordance with section 403 (r)(6) of the Federal Drug Administration (FDA). The company now has plans to develop a U.S. registration dossier for IMM-124E for Travellers’ Diarrhea. Immuron’s second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients. These products together with the Company’s other preclinical immunotherapeutic assets currently under development targeting infectious diseases are anticipated to meet pressing needs in the global immunotherapy market. To learn more about Immuron, read the company’s latest presentation: ml.globenewswire.com/Resource/Download/ 80f633ae-55eb-4635-bfc1-39a6814613c3
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Wuhan General (OTC: WUHN) Appoints Distinguished Scientist Dr. Hyder A. Khoja as Chief Scientific Officer |
| |
|
Wuhan General Group (OTC: WUHN) is positioning itself to become a major player in the $166B medical CBD space, as well as the promising psilocybin and medicinal mushroom health sector. The company announced last week that Dr. Hyder A. Khoja is joining Wuhan as Chief Scientific Officer to oversee the company’s core research and product development to commercialization.
Why It Matters: Dr. Khoja is a trusted and distinguished global leader in cannabinoid and psychedelic medicine. He possesses comprehensive knowledge of the pharmaceutical and dietary supplements industries. His extensive industrial experience spans from advising, innovating and developing cutting-edge projects, to holding various senior-level executive and senior research positions at various biotech companies, universities, and research institutes. His expertise in science and policy domains have led to a distinguished career in scientific research and business development. Dr. Khoja is excited to apply his extensive knowledge with Wuhan to advance botanical-based medicine within the realm of cannabis and mushrooms.
Key Quote: “This is a huge move forward for Wuhan to bring onboard such remarkable caliber talent as we move into drug discovery. We will be able to leverage his knowledge and our lab’s cannabis and psychedelics analytics to validate consistent medical-grade compounds for therapeutics. I expect that after we showcase our abilities, we will look for potential licensing opportunities with pharmaceutical companies.” – Jeff Robinson, CEO
Disclosure
Wuhan General Group (OTC: WUHN) pays RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| Learn about Piedmont Lithium (NASDAQ: PLL) in Exclusive Investor Group Call |
| |
|
Join Keith D. Phillips, President and CEO of Piedmont Lithium Ltd (NASDAQ: PLL), a company holding a 100% interest in the Piedmont Lithium Project in North Carolina, the only conventional lithium project in the United States, for a 15 minute presentation this Wednesday to learn about recent developments and key upcoming milestones.
Call information:
Wednesday, Aug 21 at 4 pm ET /1 pm PT
Conference Line: (866) 821-0302
About Piedmont Lithium Ltd (NASDAQ: PLL)
- Roth issued coverage in July 2019. Price target: $38.
- Holds 100% interest in Piedmont Lithium Project in world-class Carolina Tin-Spodumene Belt, one of the largest lithium provinces in the world, 25 miles west of Charlotte
- The Piedmont Lithium Project enjoys a prime location and exceptional economics. Compared to projects in Australia and Canada, North Carolina offers a lower-cost, lower-tax operating environment. In addition, the Project offers easy access to major high-tech population centers and downstream lithium-processing facilities
- Lithium is on the U.S. government’s critical minerals list, giving the Project significant strategic value as the only conventional U.S. lithium development project
- Benchmarking shows deep undervaluation vs. peers. PLL has an EV/steady-state EBITDA of ~0.3x vs. peers at 1.0x-2.5x
View Investor Deck: www.slideshare.net/RedChip/piedmont-lithium-corporate-presentation-may-2019
Want more info about the call? Reach out to the account manager:
Bruce Haase
Phone: (407) 712-8960
Email: bruce@redchip.com
Disclosure
Piedmont Lithium (NASDAQ: PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services
|
|
| |
|
| Learn about Medalist Diversified REIT (NASDAQ: MDRR) in Exclusive Investor Group Call |
| |
|
Join Thomas E. Messier, Chairman and CEO of Medalist Diversified REIT (NASDAQ: MDRR), a Virginia-based real estate investment trust that specializes in acquiring, owning and managing value-add commercial real estate in the Mid-Atlantic and Southeast regions, for a 15 minute presentation this Thursday to learn about recent developments and key upcoming milestones.
Call information:
Thursday, Aug 22 at 4 pm ET /1 pm PT
Conference Line: (866) 821-0302
About Medalist Diversified REIT (NASDAQ: MDRR)
- Dividend yield: 16.2%
- Public, Virginia-based Real Estate Investment Trust founded in 2003 as a private equity company specializing in acquiring, owning and managing value-add commercial real estate in the Southeast
- Buy rating and $5.50 price target issued by Aegis Capital in August 2019
- Management's track record as an organized, private fund dates back to 2013 through two prior Medalist funds, returning 8% and 7.5% annualized cash distributions for approximately five years and 3.5 years, respectively. The first fund has been closed and the properties have been sold, producing a total IRR of 13.3%
- Management has 50+ years' combined experience in commercial real estate and capital markets and has purchased and managed properties with a total asset value of approximately $165 million
View Investor Deck: www.slideshare.net/RedChip/medalist-diversified-reit-aug2019-presentation
Want more info about the call? Reach out to the account manager:
Craig Brelsford
Phone: (407) 571-0902
Email: craig@redchip.com
Disclosure
Medalist Diversified REIT (NASDAQ: MDRR) is a client of RedChip Companies, Inc. MDRR agreed to pay RedChip Companies, Inc. a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| |
| Quote of the Week |
| |
"If you want to invest in the microcap space buy companies not stocks, if you buy stocks, the daily fluctuations and lack of liquidity will drive you crazy."
-Byron Roth, CEO ROTH Capital |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
| | |
